Brought to you by 
Gene therapeutics developer bluebird nets $108mm through its IPO
Jun 2013
Executive Summary
Bluebird bio Inc., developer of gene transfer therapeutics, has netted $108mm through its initial public offering of 6.8mm common shares (including the overallotment) at $17. Just days before the final pricing, it had proposed selling 5mm shares between $14-16.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gene therapeutics developer bluebird nets $108mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice